

# Molecular and Integrative Toxicology

## **Series Editors**

Jamie DeWitt

East Carolina University

Greenville, NC, USA

Sarah Blossom

Arkansas Children's Hospital Research Institute

Little Rock, AR, USA

More information about this series at <http://www.springer.com/series/8792>

George A. Parker

Editor

# Immunopathology in Toxicology and Drug Development

Volume 1, Immunobiology, Investigative  
Techniques, and Special Studies

 Humana Press

*Editor*

George A. Parker  
Charles River Laboratories, Inc.  
Durham, NC, USA

ISSN 2168-4219                      ISSN 2168-4235 (electronic)  
Molecular and Integrative Toxicology  
ISBN 978-3-319-47375-8              ISBN 978-3-319-47377-2 (eBook)  
DOI 10.1007/978-3-319-47377-2

Library of Congress Control Number: 2016955830

© Springer International Publishing AG 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Humana Press imprint is published by Springer Nature  
The registered company is Springer International Publishing AG  
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

# Preface

This book provides a fundamental understanding of immunopathology and immunopathologic processes, with particular attention to nonclinical toxicology studies. Chapters provide an overview of general immunobiology, cells of the immune system, signaling and effector molecules, and immunopathology assays. A companion volume, *Immunopathology in Toxicology and Drug Development: Volume 2, Organ Systems*, offers summaries of organ-specific immunobiology and immunopathology as well as common responses to xenobiotics.

These informative and strategic books were created in response to the large segment of drug development that focuses on chronic diseases, many of which involve alterations to the immune system. Therapies that target these diseases commonly involve some form of immunomodulation. As a result, the two volumes of *Immunopathology in Toxicology and Drug Development* are critical texts for individuals involved in diverse aspects of drug development. Readers will acquire a thorough understanding of immunopathology for detection and accurate interpretation of pathologic effects of xenobiotics on the immune system.

Durham, NC

George A. Parker

# Contents

<b>1</b>	<b>Basic Immunobiology</b> . . . . .	<b>1</b>
	George A. Parker and Tracey L. Papenfuss	
1.1	Introduction . . . . .	1
1.2	General Purpose, Function and Characteristics of the Immune System . . . . .	2
1.2.1	Phylogeny of the Immune System . . . . .	2
1.2.2	Overview of Organs and Tissues of the Immune System . . . . .	4
1.2.3	Primary Immune System Organs . . . . .	4
1.2.4	Secondary Immune System Organs . . . . .	5
1.2.5	Tertiary Lymphoid Tissue . . . . .	6
1.2.6	Non-immune Organs with Non-specific and Specific Immunologic Functions . . . . .	8
1.3	Innate Immune System Overview . . . . .	9
1.3.1	Signaling Pathways of the Innate Immune System . . . . .	10
1.3.2	Natural Antibodies . . . . .	12
1.3.3	Complement . . . . .	13
1.3.4	Cells of the Innate Immune System . . . . .	15
1.3.5	Antigen Processing and Presentation . . . . .	22
	1.3.5.1 MHC Class I . . . . .	23
	1.3.5.2 MHC Class II . . . . .	24
1.4	Adaptive Immune System Overview . . . . .	26
1.4.1	CD4 <sup>+</sup> T Cell Activation and Function . . . . .	27
1.4.2	CD4 <sup>+</sup> Helper T Cell Populations . . . . .	30
1.4.3	CD8 <sup>+</sup> T Cell Activation and Function . . . . .	32
1.4.4	B Cells: Activation, Antibody Production and Generation of Humoral Responses . . . . .	34
1.5	Regulation of the Immune Response . . . . .	37
1.5.1	Cytokines . . . . .	37
1.5.2	Chemokines . . . . .	41
1.5.3	Interferon Type I . . . . .	43
1.5.4	Extracellular Vesicles/Exosomes and Immunity . . . . .	44

1.6	Refinement of Immune Responses. . . . .	45
1.6.1	Affinity Maturation . . . . .	45
1.6.2	Generation of Immunological Memory . . . . .	45
1.6.2.1	Memory B Cells . . . . .	46
1.6.2.2	Memory T Cells . . . . .	47
1.7	Immune Responses to Infectious Diseases . . . . .	48
1.8	Adverse or Nonspecific Immune Activation and Immune Dysregulation. . . . .	51
1.8.1	Accidental or Incidental Immunologic Activation. . . . .	51
1.8.2	Heterologous Immunity . . . . .	52
1.8.3	Hypersensitivity Reactions Type I–V . . . . .	53
1.8.4	Immune Dysregulation in Cancer . . . . .	53
1.8.5	Immunosenescence . . . . .	55
1.8.6	Cytokine Storm . . . . .	56
1.8.7	Eicosanoid Storm. . . . .	58
1.9	Major Ancillary Concepts and Processes. . . . .	59
1.9.1	Leukocyte Emigration and Chemotaxis. . . . .	59
1.9.2	Programmed Cell Death and Immunity . . . . .	61
1.9.3	Autophagy and Immunity . . . . .	63
1.9.4	Microbiome and Immunity . . . . .	67
	References. . . . .	70
<b>2</b>	<b>Cells of the Immune System. . . . .</b>	<b>95</b>
	George A. Parker	
2.1	Introduction . . . . .	96
2.2	Primary Immune System Cells . . . . .	96
2.2.1	Cells of the Innate Immune System. . . . .	96
2.2.1.1	Monocytes and Macrophages . . . . .	98
2.2.1.2	Neutrophils . . . . .	103
2.2.1.3	Eosinophils, Basophils & Mast Cells . . . . .	109
2.2.1.4	NK & NKT Cells . . . . .	121
2.2.1.5	Innate Lymphoid Cells (MAIT Cells and iNKT Cells) . . . . .	122
2.2.1.6	Myeloid Suppressor Cells. . . . .	123
2.2.2	Cells of the Adaptive Immune System . . . . .	124
2.2.2.1	T Lymphocytes . . . . .	125
2.2.2.2	B Lymphocytes and Plasma Cells. . . . .	134
2.2.2.3	Dendritic Cells . . . . .	137
2.2.2.4	Stromal Cells. . . . .	143
2.3	Cells of Tissues with Secondary Immune Functions. . . . .	151
2.3.1	Liver. . . . .	151
2.3.1.1	Kupffer Cells. . . . .	152
2.3.1.2	Liver-adapted NK Cells (‘pit cells’) and NKT Cells . . . . .	153
2.3.1.3	Sinusoidal Endothelial Cells. . . . .	154

2.3.1.4	Hepatocytes . . . . .	156
2.3.1.5	Intrahepatic Dendritic Cells . . . . .	157
2.3.2	Intestinal Cells . . . . .	158
2.3.2.1	Mucosal Epithelial Cells . . . . .	158
2.3.2.2	Tuft Cells . . . . .	158
2.3.2.3	Paneth Cells . . . . .	158
2.3.2.4	NK Cells/Large Granule Leukocytes . . . . .	160
References.	. . . . .	162
<b>3</b>	<b>Signaling and Effector Molecules in Immunity . . . . .</b>	<b>203</b>
	Michael C. Milone	
3.1	Introduction . . . . .	203
3.1.1	Innate Immune Recognition . . . . .	204
3.1.1.1	Pattern Recognition Receptors (PRRs) . . . . .	204
3.1.1.2	Toll-Like Receptors (TLRs) . . . . .	205
3.1.1.3	PRRs Beyond the TLRs . . . . .	207
3.1.1.4	The “Inflammasome” as a Unique Signaling Complex Driving Inflammation . . . . .	208
3.1.1.5	NF- $\kappa$ B: A Master Regulator of Inflammation . . . . .	210
3.1.2	Adaptive Immune Recognition . . . . .	211
3.1.2.1	T Cell Receptor (TCR) . . . . .	211
3.1.2.2	B Cell Receptor (BCR) and Antibodies . . . . .	213
3.1.3	Immune Recognition that Blurs the Lines Between Innate and Adaptive Immunity . . . . .	214
3.1.3.1	Fc Receptors . . . . .	214
3.1.3.2	NK Cell-Associated Receptors . . . . .	215
3.1.3.3	KIR and Ly-49 Families of Receptors . . . . .	216
3.1.3.4	CD94: NKG2A/C Receptors . . . . .	217
3.1.3.5	NKG2D: A Receptor for Altered Self . . . . .	218
3.1.3.6	Natural Cytotoxicity Receptors (NCRs) . . . . .	219
3.1.4	Immune Effector Molecules . . . . .	219
3.1.4.1	Defensins and Other Antimicrobial Peptides . . . . .	219
3.1.4.2	Complement . . . . .	220
3.1.4.3	Cytokines . . . . .	223
References.	. . . . .	235
<b>4</b>	<b>Development of Immune System Organs . . . . .</b>	<b>245</b>
	George A. Parker	
4.1	Introduction . . . . .	248
4.2	Embryogenesis and Organogenesis of the Immune System Organs . . . . .	248
4.2.1	Bone Marrow and Liver . . . . .	249
4.2.2	Thymus . . . . .	251
4.2.3	Spleen . . . . .	255

4.2.4	Lymph Nodes . . . . .	258
4.2.5	Mucosa-Associated Lymphoid Tissue (MALT) . . . . .	262
4.3	Postnatal Development of Immune System Organs . . . . .	264
4.3.1	Bone Marrow and Liver . . . . .	264
4.3.2	Thymus . . . . .	266
4.3.3	Spleen . . . . .	270
4.3.4	Lymph Nodes . . . . .	273
4.3.5	Mucosa-Associated Lymphoid Tissue (MALT) . . . . .	277
4.3.5.1	Gut-Associated Lymphoid Tissue (GALT) . . . . .	278
4.3.5.2	Bronchus-Associated Lymphoid Tissue (BALT) . . . . .	285
4.3.5.3	Nasopharynx-Associated Lymphoid Tissue (NALT) . . . . .	286
4.4	Tertiary Lymphoid Tissue and Milky Spots . . . . .	288
	References . . . . .	288
<b>5</b>	<b>Aging of Immune System Organs . . . . .</b>	<b>295</b>
	George A. Parker	
5.1	Introduction . . . . .	296
5.2	General Features of Immunosenescence . . . . .	297
5.3	Effects of Aging on Hematopoietic Stem Cells and Committed Lymphoid Progenitor Cells . . . . .	297
5.4	Effects of Aging on the Innate Immune System . . . . .	298
5.4.1	Effects of Aging on Neutrophils . . . . .	300
5.4.2	Effects of Aging on Monocytes and Macrophages . . . . .	302
5.4.3	Effects of Aging on Dendritic Cells . . . . .	303
5.4.4	Effects of Aging on NK Cells . . . . .	305
5.4.5	Effects of Aging on NKT Cells . . . . .	305
5.4.6	Effects of Aging on Mast Cells and Eosinophils . . . . .	306
5.5	Effects of Aging on the Adaptive Immune System . . . . .	307
5.5.1	Effects of Aging on T Cells . . . . .	307
5.5.2	Effects of Aging on B Cells . . . . .	311
5.5.3	Effects of Aging on the Germinal Center Reaction . . . . .	312
5.6	Effects of Aging on Cytokines . . . . .	313
5.7	Clinical Effects of Immunosenescence . . . . .	313
5.8	Histomorphology of Immunosenescence . . . . .	314
5.8.1	Histomorphological Effects of Aging on the Bone Marrow . . . . .	315
5.8.2	Histomorphological Effects of Aging on the Thymus . . . . .	316
5.8.3	Histomorphological Effects of Aging on the Spleen . . . . .	321
5.8.4	Histomorphological Effects of Aging on Lymph Nodes . . . . .	325
5.9	Summary Points . . . . .	329
	References . . . . .	330



<b>6</b>	<b>Flow Cytometry and Immunophenotyping in Drug Development</b> .....	343
	Tracey L. Papenfuss	
6.1	Introduction .....	344
6.2	Uses of Flow Cytometry in Toxicology .....	348
6.2.1	Early Discovery .....	348
6.2.2	Safety Assessment and Toxicology .....	349
6.2.3	Clinical Testing and Monitoring .....	349
6.3	Considerations in the Implementation of Flow Cytometric Analysis .....	351
6.3.1	General Considerations .....	351
6.3.2	Instrumentation .....	356
6.3.3	Sample Collection and Processing for Immediate Flow Cytometric Analysis .....	357
6.3.4	Advanced and Enhanced Sample Preparation .....	358
6.3.5	Sample Preservation and Storage for Delayed Flow Cytometric Analysis .....	359
6.3.6	Antibodies .....	360
6.3.7	Data Acquisition, Compensation, Controls and Thresholds .....	361
6.3.8	Data Analysis and Reporting .....	362
6.3.9	Validation .....	363
6.4	Integration of Flow Cytometry with Other Investigative Techniques in Drug Development .....	364
6.5	Conclusions .....	364
	References .....	365
<b>7</b>	<b>Pathology Evaluation for Detection of Immunomodulation</b> .....	371
	George A. Parker and Paul W. Snyder	
7.1	Introduction .....	373
7.2	Necropsy and Histotechnology .....	374
7.2.1	Fixation of Tissue Specimens for Routine Histopathological Evaluation .....	376
7.2.2	Histotechnique Considerations for Immune System Organs .....	376
7.3	Organ Weight Evaluation .....	379
7.4	Histopathology .....	379
7.4.1	Morphological Alterations in Organs of the Immune System .....	380
7.4.1.1	Germinal Center Reaction .....	384
7.4.2	Secondary Evidence of Immune System Dysfunction .....	390
7.4.3	Stress Response Versus Immunomodulation .....	391
7.4.4	Adverse Versus Non-adverse Determinations .....	396
7.5	Special Circumstances in the Pathology Evaluation .....	398
7.5.1	Studies Conducted in Juvenile Animals .....	398
7.5.2	Studies Involving Biologics .....	399

7.5.3	Immunomodulatory Experimental Procedures and Vehicles . . . . .	402
7.5.3.1	Infusion Studies . . . . .	402
7.5.3.2	Saline Infusion or Injection . . . . .	404
7.5.3.3	Polyethylene Glycol-Conjugated Test Articles . . . . .	404
7.5.4	Immunomodulation Due to Concurrent Disease . . . . .	405
7.5.4.1	Auricular Chondritis . . . . .	405
7.5.4.2	Inflammatory Foot Lesions in Rats . . . . .	406
7.5.5	Syphacea Infestation . . . . .	407
7.5.6	CAR Bacillus Infection . . . . .	409
7.5.7	Murine Mycoplasmosis . . . . .	410
7.5.8	Reactivated Viral Infections in Nonhuman Primates . . . . .	412
7.5.9	Candidiasis as a Complication of Immunomodulation . . . . .	415
7.5.10	Demodex-Related Skin Lesions . . . . .	420
7.5.11	Oesophagostomiasis in Nonhuman Primates . . . . .	421
7.5.12	<i>Pneumonyssus</i> Mites and Lung Pigment in Nonhuman Primates . . . . .	421
7.5.13	Cercopithecine Herpesvirus Type-1 (Herpes B virus) in Nonhuman Primates . . . . .	422
7.5.14	Atypical Infections . . . . .	422
7.5.15	Non-specific Inflammatory Lesions . . . . .	423
7.5.16	Amyloid Deposition in Tissues . . . . .	424
7.5.17	Pseudoamyloid . . . . .	425
7.5.18	Miscellaneous Histologic Changes . . . . .	426
7.6	'Whole Animal' Approach to Immunopathology . . . . .	428
7.7	Summary Points . . . . .	431
	References . . . . .	432
<b>8</b>	<b>Enhanced Immunohistopathology . . . . .</b>	<b>443</b>
	Susan A. Elmore	
8.1	Introduction and Historical Perspective . . . . .	443
8.2	Enhanced Histopathology Defined . . . . .	444
8.3	Methodology and Organ-Specific Examples of Enhanced Histopathology . . . . .	445
8.3.1	Evaluation of the Thymus . . . . .	447
8.3.2	Evaluation of the Bone Marrow . . . . .	448
8.3.3	Evaluation of the Spleen . . . . .	450
8.3.4	Evaluation of the Lymph Nodes . . . . .	450
8.3.5	Evaluation of the Mucosa-Associated Lymphoid Tissue . . . . .	451
8.4	Points to Consider and Caveats . . . . .	452
	References . . . . .	455

<b>9</b>	<b>Clinical Pathology Assays in Immunopathology</b> . . . . .	457
	Josely F. Figueiredo, Kirstin F. Barnhart, and Niraj Tripathi	
9.1	Introduction . . . . .	457
9.2	Clinical Pathology Testing . . . . .	458
9.2.1	Hematology . . . . .	458
9.2.1.1	Leukocytes . . . . .	459
9.2.1.2	Red Blood Cells . . . . .	462
9.2.1.3	Platelets . . . . .	463
9.2.2	Cytological Evaluation of Bone Marrow . . . . .	463
9.2.3	Clinical Chemistry . . . . .	465
9.2.3.1	Globulins . . . . .	465
9.2.3.2	Acute Phase Proteins . . . . .	468
9.2.4	Urinalysis . . . . .	469
9.2.5	Coagulation . . . . .	470
9.2.6	Hormones . . . . .	472
9.2.7	Autoantibodies . . . . .	473
9.2.7.1	Anti-platelet Antibodies . . . . .	474
9.2.7.2	Anti-erythrocyte Antibodies . . . . .	475
9.2.7.3	Systemic Autoantibodies . . . . .	477
9.2.8	Complement . . . . .	478
9.2.9	Cytokines . . . . .	480
	References . . . . .	481
<b>10</b>	<b>Application of Immunohistochemistry in Toxicologic Pathology of the Hematolymphoid System</b> . . . . .	489
	Jerold E. Rehg and Jerrold M. Ward	
10.1	Introduction . . . . .	489
10.2	Technical Considerations . . . . .	490
10.2.1	Tissue Preparation and Fixation . . . . .	490
10.2.2	Fixative and Fixation Time . . . . .	496
10.2.3	Decalcification . . . . .	496
10.2.4	Immunohistochemistry Fundamentals . . . . .	496
10.2.5	Specific Staining . . . . .	497
10.2.6	Controls . . . . .	497
10.2.7	Antibodies and Antigens for FFPE Tissues . . . . .	498
10.3	Panleukocyte Antigen . . . . .	498
10.4	B-Cell and Plasma Cell Lineage Antigens . . . . .	498
10.4.1	B-Cell Antigens . . . . .	498
10.4.2	Immunoglobulins . . . . .	501
10.4.3	Plasma Cell Antigens . . . . .	501
10.5	T-, NK-T and NK Cell Lineage Antigens . . . . .	502
10.6	Other Lymphoid Antigens . . . . .	508
10.7	Myeloid Lineage Antigens . . . . .	511
10.7.1	Undifferentiated Myeloid Antigens . . . . .	511
10.7.2	Common Granulocyte and Monocyte Antigens . . . . .	512

- 10.7.3 Erythroid Cell Antigens . . . . . 513
- 10.7.4 Megakaryocyte Antigens . . . . . 514
- 10.7.5 Eosinophil Antigens . . . . . 515
- 10.7.6 Mast Cell and Basophil Antigens. . . . . 515
- 10.7.7 Tissue Histiocyte (Macrophage) Antigens. . . . . 518
- 10.7.8 Dendritic Lineage Antigens . . . . . 523
- 10.8 Proliferation and Apoptotic Antigens . . . . . 524
  - 10.8.1 Proliferation Antigens . . . . . 524
  - 10.8.2 Apoptosis Antigens . . . . . 526
  - 10.8.3 Cross-Species Immunoreactivity of Antibodies. . . . . 526
  - 10.8.4 Rat, Monkey, Dog, and Pig Lymphoid  
Immunohistochemistry. . . . . 526
- 10.9 Examples of the Use of IHC for Evaluating the  
Hematolymphoid System. . . . . 528
  - 10.9.1 Assessment of the Normal Expression Patterns  
of Hematolymphoid Cells in Lymphoid Tissue  
and Bone Marrow. . . . . 528
  - 10.9.2 Development of Abnormal Patterns of Antigen  
Expression in Lymphoid Cells and Tissues after  
Exposure to Toxins and Toxicants and  
in Neoplasia . . . . . 530
  - 10.9.3 Loss of an Antigen Commonly Associated  
with a Cell . . . . . 533
  - 10.9.4 Alterations in the Number or Distribution  
of Hematolymphoid Cells in a Tissue . . . . . 534
  - 10.9.5 Changes in the Expression of Antigens Associated  
with a Cell . . . . . 536
  - 10.9.6 Identification of Hematolymphoid Cells Associated  
with an Inflammatory Lesion . . . . . 536
  - 10.9.7 Cell Proliferation Markers . . . . . 540
  - 10.9.8 Diagnosis of Hematolymphoid Disorders . . . . . 542
  - 10.9.9 Diagnosis of Myeloid Proliferations . . . . . 543
  - 10.9.10 Diagnosis of Lymphoma . . . . . 548
  - 10.9.11 IHC Criteria for B-Cell Malignancy . . . . . 548
  - 10.9.12 IHC Criteria for T-Cell Malignancy. . . . . 549
- References. . . . . 551

- 11 Morphometry and Stereology in Immunopathology . . . . . 563**  
Danielle L. Brown and Cynthia L. Swanson
  - 11.1 Introduction . . . . . 563
  - 11.2 Histomorphometry in Immunopathology . . . . . 564
  - 11.3 Limitations of Histomorphometry . . . . . 568
  - 11.4 Stereology in Immunopathology . . . . . 570
    - 11.4.1 Tissue Sampling for Stereology. . . . . 570

11.4.2	Sampling Fields of View and Applying Stereological Probes . . . . .	575
11.4.3	Applications of Stereology in Immunopathology . . . . .	577
	References . . . . .	582
<b>12</b>	<b>Molecular Techniques in Immunopathology . . . . .</b>	<b>585</b>
	Bevin Zimmerman, Jason Aligo, and Daniel Weinstock	
12.1	Introduction . . . . .	585
12.2	Sample Preparation for Molecular Analysis . . . . .	587
12.2.1	Procurement and Fixation . . . . .	587
12.2.2	Processing and Storage . . . . .	588
12.3	Polymerase Chain Reaction (PCR) . . . . .	589
12.4	In Situ Hybridization . . . . .	590
12.4.1	Probe Design and Label Selection . . . . .	591
12.4.1.1	Probe Generation—Traditional Approaches . . . . .	591
12.4.1.2	Radiolabeled Probes . . . . .	592
12.4.1.3	Hapten-Conjugated Probes . . . . .	592
12.4.1.4	Fluorescent Labeled Probes . . . . .	593
12.4.1.5	Branched DNA Probe Technology . . . . .	594
12.4.2	Validation Strategies and Selection of Controls . . . . .	595
12.5	Next Generation Sequencing . . . . .	596
12.6	Examples of Molecular Techniques Added Value in Drug Development . . . . .	596
12.7	Utility of Molecular Techniques as Companion Diagnostics . . . . .	597
12.8	Summary . . . . .	598
	References . . . . .	598
<b>13</b>	<b>Current Issues in Developmental Immunotoxicity . . . . .</b>	<b>601</b>
	Jamie C. DeWitt and Deborah E. Keil	
13.1	What Is Developmental Immunotoxicity (DIT)? . . . . .	601
13.1.1	DIT Defined . . . . .	601
13.1.2	Current Methods of Evaluating DIT . . . . .	602
13.2	Critical Windows of Immune System Development . . . . .	604
13.2.1	Overview of the Developing Immune System . . . . .	604
13.2.1.1	Early-Life Risk . . . . .	604
13.2.1.2	Vulnerability of the Developing Immune System . . . . .	605
13.2.1.3	Critical Stages of Immunological Maturation . . . . .	605
13.2.1.4	Epigenetics and Its Role in Immunological Development . . . . .	606
13.2.1.5	One Xenobiotic, Multiple Mechanisms of Action . . . . .	607

13.2.2	Examples from Established Developmental Immunotoxicants . . . . .	608
13.3	Lifetime Risks After DIT. . . . .	609
13.3.1	Diseases with Known DIT Risk Factors . . . . .	609
13.3.2	Disease Patterns Thought to be Associated with DIT. . . . .	609
13.3.3	Monitoring the Impact of Early-Life Environmental Factors on the Immune System for Prevention of Disease Strategies in Old Age . . . . .	610
13.4	Why Is There a Need for DIT Testing of Chemical Substances? . . . . .	611
13.5	Toxicology in the Twenty-First Century and DIT . . . . .	611
13.5.1	Tox21 Defined . . . . .	611
13.5.2	Tox21 and Developmental Endpoints . . . . .	612
13.5.3	Tox21 and TSCA in the US . . . . .	613
13.6	Alternative Methods of Detecting DIT . . . . .	614
13.7	What the Future Holds. . . . .	614
	References. . . . .	615
<b>14</b>	<b>The Murine Local Lymph Node Assay . . . . .</b>	<b>619</b>
	Ton van Huygevoort	
14.1	Introduction: Allergic Contact Dermatitis . . . . .	620
14.2	Animal Models . . . . .	621
14.3	Delayed Type IV Hypersensitivity Response . . . . .	623
14.4	The Local Lymph Node Assay (LLNA) Principle. . . . .	625
14.5	Alternative Methods for the Assessment of Cell Proliferation . . . . .	630
14.6	Critical Performance Factors . . . . .	631
14.7	LLNA Negative and Positive Control Data . . . . .	632
14.8	Limitations to the LLNA . . . . .	633
14.9	Advantages to the LLNA. . . . .	634
14.10	Non-Animal Models . . . . .	635
	References. . . . .	636
<b>15</b>	<b>Host Resistance Assays for Efficacy and Immunotoxicology Safety Evaluations . . . . .</b>	<b>639</b>
	Gary R. Burleson, Stefanie C. M. Burleson, and Florence G. Burleson	
15.1	Approaches to Evaluate Immunotoxicity . . . . .	640
15.1.1	Standard Toxicity Studies (STS) . . . . .	640
15.1.2	Functional Assays . . . . .	640
15.1.3	Host Resistance Assays (Animal Disease Models): The “Gold Standard” . . . . .	642
15.2	Comprehensive Host Resistance Assay . . . . .	643
15.2.1	Influenza Virus Host Resistance Assay . . . . .	643

- 15.3 Targeted Host Resistance Assays . . . . . 644
  - 15.3.1 Bacterial Host Resistance Assays . . . . . 644
    - 15.3.1.1 Evaluation of Neutrophil and/or Macrophage Function . . . . . 644
    - 15.3.1.2 Evaluation of Anti-Inflammatory Therapeutics . . . . . 646
    - 15.3.1.3 Evaluation of Therapeutics Targeting TNF- $\alpha$  . . . . . 646
    - 15.3.1.4 Marginal Zone B (MZB) Cell Evaluation . . . . . 646
  - 15.3.2 Viral Reactivation Host Resistance Assay . . . . . 647
    - 15.3.2.1 Murine Cytomegalovirus (MCMV) Latent Viral Model . . . . . 648
    - 15.3.2.2 Murine Gamma Herpesvirus 68 (MVH-68) Latent Viral Reactivation Model . . . . . 648
  - 15.3.3 Fungal Host Resistance . . . . . 648
- References . . . . . 648
- Index** . . . . . 651

# About the Editor

**George A. Parker**, a leading expert in the field of toxicologic pathology, is currently a Senior Scientific Director, Global Pathology, at Charles River Laboratories. Dr. Parker is a graduate of Auburn University College of Veterinary Medicine and completed a residency program in veterinary pathology at the Armed Forces Institute of Pathology, as well as a Ph.D. program in molecular and cellular immunology at the University of Medicine and Dentistry of New Jersey. He is a board-certified pathologist and toxicologist as well as a fellow of the distinguished International Academy of Toxicologic Pathology. He has more than 35 years of experience in the field of toxicologic pathology, with an emphasis on the nonclinical safety assessment of drugs, agricultural chemicals, and industrial chemicals. Dr. Parker's areas of specific expertise include immunopathology, toxicologic pathology of juvenile animals, and radiation pathology.



# Contributors

**Jason Aligo** Biologics Toxicology, Janssen Research & Development, LLC, Spring House, PA, USA

**Kirstin F. Barnhart** AbbVie, North Chicago, IL, USA

**Danielle L. Brown** Charles River Laboratories, Inc., Durham, NC, USA

**Florence G. Burleson** Burleson Research Technologies, Inc. (BRT), Morrisville, NC, USA

**Gary R. Burleson** Burleson Research Technologies, Inc. (BRT), Morrisville, NC, USA

**Stefanie C.M. Burleson** Burleson Research Technologies, Inc. (BRT), Morrisville, NC, USA

**Jamie C. DeWitt** Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC, USA

**Susan A. Elmore** National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA

**Josely F. Figueiredo** Charles River Laboratories, Inc., Ashland, OH, USA

**Deborah E. Keil** Department of Microbiology and Immunology, Montana State University, Bozeman, MT, USA

**Michael C. Milone** Toxicology and Therapeutic Drug Monitoring Laboratory, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

**Tracey L. Papenfuss** Charles River Laboratories, Inc., Ashland, OH, USA

**George A. Parker** Charles River Laboratories, Inc., Durham, NC, USA

**Jerold E. Rehg** Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA

**Paul W. Snyder** Experimental Pathology Laboratories, Inc., West Lafayette, IN, USA

**Cynthia L. Swanson** Charles River Laboratories, Inc., Durham, NC, USA

**Niraj Tripathi** Covance Laboratories, Madison, WI, USA

**Ton van Huygevoort** Charles River Laboratories, Inc., Charles River Den Bosch, 's-Hertogenbosch, The Netherlands

**Jerrold M. Ward** Global VetPathology, Montgomery, MD, USA

**Daniel Weinstock** Biologics Toxicology, Janssen Research & Development, LLC, Spring House, PA, USA

**Bevin Zimmerman** Preclinical Development & Safety, Janssen Research & Development, LLC, Spring House, PA, USA